Takeaway
- In patients with stage II colon cancer, an approach based on circulating tumour DNA (ctDNA) reduces the use of adjuvant chemotherapy without compromising recurrence risk.
- ctDNA-positive patients are likely to benefit from adjuvant chemotherapy, while ctDNA-negative patients are not.
Why this matters
- Surgery can cure more than 80% of...